Agilent | Trusted AnswersAgilent | Trusted Answers

TNBC Indication SK006 PD-L1 IHC 22C3 pharmDx Launch

20 July 2022 | 2:00 p.m. GMT +7 

Triple Negative Breast Cancer in Thailand

Every year, nearly 22,000 women in Thailand are reported to be diagnosed with breast cancer, with over 8000 of these cases ending in death.

Agilent is committed to fight cancer. Join us as we launch the latest indication on PD-L1 IHC 22C3 pharmDx for Triple Negative Breast Cancer (TNBC).

Opening Address


Panadda Yanapirat

Medicare Supply Ltd. Part.


Launch of TNBC

An overview of the new TNBC indication approved for PD-L1 IHC 22C3 pharmDx in Thailand

Stefanie Scheer

Global Product Marketing
Agilent Technologies, Denmark



PD-L1 22C3 IHC Testing in TNBC

Guiding Immune Checkpoint Inhibitor Therapy in Thailand

Dr Kroonpong Iampenkhae, MD.

Main Consultant for Breast Pathology,
King Chulalongkorn Memorial Hospital